InsiderTrades

Form 4 for REGN Regeneron Pharmaceuticals

Accepted 2023-02-08 00:00:00 ET · period of report 2023-02-06 · accession 0001883850-23-000045 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-02-08 2023-02-06 REGN BROWN MICHAEL S Dir S - Sale+OE $798.00 -3,071 1,247 -71% -$2.45M
D 2023-02-08 2023-02-06 REGN BROWN MICHAEL S Dir M - OptEx $520.01 +3,071 4,318 +246% +$1.60M
DI 2023-02-08 2023-02-06 REGN BROWN MICHAEL S Dir S - Sale+OE $797.00 -500 6,162 -8% -$398.5K
D 2023-02-08 2023-02-06 REGN BROWN MICHAEL S Dir M - OptEx $0.00 -3,071 3,070 -50% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-02-06 S D 3,071 $798.00 1,247 D — —
2 Common Common Stock 2023-02-06 M A 3,071 $520.01 4,318 D by Trust — —
3 Common Common Stock 2023-02-06 S D 500 $797.00 6,162 I — —
4 Derivative Non-Qualified Stock Option (right to buy) 2023-02-06 M D 3,071 $0.00 3,070 D $520.01 · — to 2026-01-04 3,071 Common Stock (F3) The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.